The treatment landscape for multiple myeloma, a deadly cancer of the bone marrow that affects about 30,000 Americans every year, has changed significantly over the past decade. And more changes look to be on the way. Take the results of a Phase 3 study just reported today at the American Society of Hematology’s (ASH) yearly […]
Original Article: BCMA Day: At ASH ‘18, Cell Therapies For Myeloma Take Center Stage